Soleno Therapeutics (SLNO) Receivables - Other (2013 - 2019)
Soleno Therapeutics (SLNO) posted quarterly Receivables - Other of $9000.0 for Q3 2019, down 50.0% quarter-over-quarter from $18000.0 in Q2 2019.
Soleno Therapeutics (SLNO) Receivables - Other (2013 - 2019) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Receivables - Other for 4 consecutive years, with $9000.0 the latest figure, recorded in Q3 2019.
- In Q3 2019, Receivables - Other changed N/A year-over-year to $9000.0; the TTM figure through Sep 2019 stood at $9000.0 (changed N/A YoY), while the FY2018 annual figure was $64000.0, changed N/A from the prior year.
- Receivables - Other slipped to $9000.0 in Q3 2019 per SLNO's latest filing, from $18000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $72000.0 in Q1 2019 and bottomed at $9000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 9,000.00 |
| Sep 30, 2019 | 9,000.00 |
| Jun 30, 2019 | 18,000.00 |
| Jun 30, 2019 | 18,000.00 |
| Mar 31, 2019 | 72,000.00 |
| Mar 31, 2019 | 72,000.00 |
| Dec 31, 2018 | 64,000.00 |
| Dec 31, 2018 | 64,000.00 |
| Mar 31, 2014 | 41,000.00 |
| Mar 31, 2014 | 41,000.00 |
| Dec 31, 2013 | 218.00 |
| Dec 31, 2013 | 218.00 |